In­flaRx wins FDA emer­gency use au­tho­riza­tion for Covid an­ti­body

In­flaRx’s mon­o­clon­al an­ti­body vilo­be­limab has re­ceived emer­gency use au­tho­riza­tion to treat crit­i­cal­ly ill Covid-19 pa­tients on in­va­sive me­chan­i­cal ven­ti­la­tion.

Vilo­be­limab, which will be sold un­der the brand name Go­hibic, was cleared for use in hos­pi­tal­ized adults with­in 48 hours of re­ceiv­ing in­va­sive me­chan­i­cal ven­ti­la­tion or ex­tra­cor­po­re­al mem­brane oxy­gena­tion, ac­cord­ing to In­flaRx. The Ger­man biotech said it’s ramp­ing up pro­duc­tion and will roll out the drug as soon as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER